Is Egrifta (Tesamorelin) Legal in Virginia?

Federal Legal Framework for Tesamorelin

Tesamorelin is a synthetic analogue of growth-hormone-releasing hormone (GHRH). The FDA approved the branded product Egrifta on November 10, 2010, under NDA 022505, specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. [1] A higher-concentration formulation, Egrifta SV, received approval in 2019 under the same indication. [2]

Because the FDA has approved tesamorelin as a finished drug product, it is not a research chemical or a gray-area compound. It is a prescription drug governed by 21 U.S.C. § 353, meaning a valid prescriber-patient relationship and a written (or electronic) prescription are required before any pharmacy may dispense it.

Controlled Substance Status

Tesamorelin does not appear in any schedule of the Controlled Substances Act (CSA). [3] The Drug Enforcement Administration (DEA) has not scheduled GHRH analogues as a class. This means possession of a legitimately dispensed supply is not subject to the quantity limits, record-keeping mandates, or criminal penalties that apply to, say, testosterone or growth hormone itself. Growth hormone (somatropin) is separately scheduled under 21 U.S.C. § 333(e), but tesamorelin is a releasing-factor peptide, not somatropin, and that statute does not extend to it.

FDA Approval vs. Off-Label Prescribing

Approval for a single indication does not prevent physicians from prescribing a drug for other conditions. The FDA regulates drug manufacturers, not medical practice. A Virginia-licensed physician, nurse practitioner, or physician assistant operating within their scope of practice may prescribe tesamorelin off-label (for example, for age-related GH decline or body-composition purposes) provided the clinical decision is supported by medical evidence and documented in the patient record.

The American Association of Clinical Endocrinology (AACE) has published position statements emphasizing that off-label use of growth-axis agents requires careful patient selection and monitoring. [4] Prescribers who deviate from approved labeling without adequate documentation face licensure and liability exposure, not federal criminal liability.

Virginia State Law and the Medical Practice Act

Virginia has no statute that independently restricts tesamorelin beyond the federal prescription-drug framework. The relevant Virginia codes are:

• Code of Virginia § 54.1-3408: Requires a valid prescription from a practitioner licensed in Virginia before a pharmacy may dispense a prescription drug.
• Code of Virginia § 54.1-3300 et seq. (Pharmacy Practice Act): Governs pharmacy licensure and dispensing standards.
• Code of Virginia § 54.1-2900 et seq. (Medical Practice Act): Defines prescribing authority for physicians, nurse practitioners, and physician assistants.

None of these statutes name tesamorelin or GHRH analogues as prohibited or restricted substances. [5] The Virginia Department of Health Professions (DHP) enforces professional conduct standards; a prescriber who issues tesamorelin prescriptions without a legitimate clinical basis could face discipline under those standards, but the molecule itself is not contraband.

Virginia Board of Pharmacy Oversight

The Virginia Board of Pharmacy oversees all licensed pharmacies operating in the state. A Virginia-licensed pharmacy, including a mail-order pharmacy licensed to ship into Virginia, may dispense Egrifta or Egrifta SV provided it receives a valid prescription. The Board has not issued any advisory opinion restricting tesamorelin dispensing as of January 2025.

Telehealth Prescribing in Virginia

Virginia expanded telehealth prescribing authority substantially through Code of Virginia § 54.1-3303, which was amended to allow prescriptions issued via synchronous audiovisual telemedicine when a prescriber-patient relationship exists. A Virginia-licensed telehealth provider may therefore evaluate a patient remotely, determine clinical appropriateness, and issue a tesamorelin prescription that a Virginia (or out-of-state, if licensed there) pharmacy can fill. The prescriber must still be licensed in the state where the patient is physically located at the time of the visit. [6]

Compounded Tesamorelin: A More Complex Picture

The compounding-pharmacy question deserves its own careful treatment, because this is where the legal framework is genuinely more complicated.

What Is a Compounding Pharmacy?

A 503A pharmacy compounds individualized preparations for specific patients under a prescription. A 503B outsourcing facility compounds larger batches without patient-specific prescriptions and ships to healthcare providers. Both types are subject to different FDA oversight levels and both must use only bulk drug substances that appear on the FDA's approved Bulks List (for 503A) or that are otherwise permitted.

Tesamorelin and the FDA Bulks List

As of January 2025, tesamorelin is not on the FDA's 503A Bulks List of bulk drug substances that compounding pharmacies may use under 21 U.S.C. § 503A. [7] This is significant. Because an FDA-approved finished product (Egrifta) exists, FDA guidance strongly discourages compounding essentially a copy of that approved product. Compounding a copy of a commercially available approved drug is generally prohibited under 503A unless the commercial product is on the FDA drug shortage list or the patient has a documented allergy to an excipient in the approved product that the compounded version would omit.

The FDA's draft guidance on compounding of drugs that are essentially copies of approved drugs states: "A compounded drug product is not an 'essentially a copy' of a commercially available drug product if the compounded drug product has a difference, due to a change in one or more active or inactive ingredients, that produces for an identified individual patient a clinically significant difference." [8]

Practical Implications for Virginia Patients

A Virginia patient who cannot tolerate mannitol or another excipient in Egrifta SV might have a legitimate basis for a compounded preparation. That scenario is narrow. For most patients, the commercially available Egrifta or Egrifta SV is the legally correct route. Patients who receive compounded tesamorelin from a pharmacy that does not meet 503A or 503B standards are receiving a product that may be technically out of compliance with FDA compounding law, even if Virginia law has not independently barred it. The physician prescribing that compound may also face scrutiny.

The HealthRX clinical team uses a three-question compliance screen before routing any Virginia tesamorelin patient to a compounding pharmacy:

1. Is Egrifta or Egrifta SV commercially available and covered (or affordable) for this patient?
2. Does the patient have a documented intolerance or allergy to a specific excipient in the commercial product?
3. Does the compounding pharmacy hold a current 503A or 503B registration with the FDA?

If the answer to question 1 is yes and question 2 is no, the patient is routed to a commercial-product prescription, not a compounding pharmacy.

How to Get a Legal Tesamorelin Prescription in Virginia

Getting tesamorelin legally in Virginia follows the same pathway as any prescription drug.

Step 1: Establish a Prescriber-Patient Relationship

A Virginia-licensed physician (MD or DO), nurse practitioner (with prescriptive authority), or physician assistant (with a practice agreement) can prescribe tesamorelin. The prescriber must conduct a medical evaluation, in-person or via compliant telehealth, and document the clinical indication.

For the FDA-approved indication, the patient must have HIV infection and excess visceral abdominal fat confirmed on clinical assessment. The key Phase 3 trial (LIPO-010, N=412) demonstrated that tesamorelin 2 mg subcutaneously daily reduced visceral adipose tissue by 18.1% versus 5.1% with placebo at 26 weeks (P<0.0001). [9] That efficacy data supports the approved indication that the prescriber documents.

Step 2: Obtain the Prescription

The prescriber transmits an electronic prescription (e-prescribing is standard in Virginia) or writes a paper prescription to a licensed pharmacy. No DEA number is required on the prescription because tesamorelin is not a controlled substance, though the prescriber's state license number must appear.

Step 3: Fill at a Licensed Pharmacy

Specialty pharmacies typically stock or can order Egrifta SV. The manufacturer (Theratechnologies) operates a patient-assistance program called "Egrifta Assist" for commercially insured, Medicaid, and uninsured patients, which may reduce or eliminate out-of-pocket costs. [2] Virginia Medicaid covers Egrifta for HIV lipodystrophy under specific prior-authorization criteria set by the Virginia Department of Medical Assistance Services.

Step 4: Patient Self-Administration

Tesamorelin is supplied as a lyophilized powder requiring reconstitution. The prescribing physician or their clinical team should train the patient on subcutaneous injection technique, sterile reconstitution, and storage (refrigerate at 2°C to 8°C before reconstitution; use within 3 hours after reconstitution). [1]

Clinical Evidence Supporting Tesamorelin

Virginia prescribers evaluating tesamorelin should be familiar with the trial data that underpins FDA approval and any off-label use decisions.

Key Trials for HIV Lipodystrophy

Two Phase 3 trials, LIPO-010 (N=412) and a parallel study conducted by Falutz et al. Published in the New England Journal of Medicine (2007, N=412), established efficacy and safety. [9, 10] Visceral adipose tissue reduction was statistically significant and clinically meaningful. Insulin-like growth factor 1 (IGF-1) levels rose, but glucose parameters remained within acceptable ranges in most participants over 26 weeks.

Long-Term Safety Data

A 52-week extension study showed that continued tesamorelin maintained VAT reduction, and discontinuation led to VAT returning toward baseline within 12 weeks. [10] This informs prescribing in Virginia clinical practice: tesamorelin is not a one-time intervention but a maintenance therapy requiring ongoing prescriber oversight and periodic reassessment.

Off-Label Considerations

The off-label use of tesamorelin for non-HIV-related body-composition changes (for example, in adults with age-associated GH decline) has generated interest, but the evidence base is thinner. A 2012 study by Falutz et al. (N=195) examined tesamorelin in non-HIV older adults with abdominal obesity and showed modest VAT reduction; however, no FDA indication exists for this population. [11] Virginia prescribers considering off-label use should document the specific clinical rationale, confirm the patient has been informed that the use is off-label, and obtain appropriate monitoring labs (fasting glucose, HbA1c, IGF-1) at baseline and at 3-month intervals.

The Endocrine Society's clinical practice guideline on adult growth hormone deficiency (2011, updated) states: "We recommend against the use of GH or GH secretagogues in healthy older adults for the purpose of reversing the effects of aging." [12] That language applies to GH secretagogues broadly, and tesamorelin, as a GHRH analogue, falls within the spirit of that caution. This does not make off-label use illegal, but it does obligate the prescriber to a higher documentation standard.

Insurance, Prior Authorization, and Cost in Virginia

Egrifta SV carries a list price exceeding $5,000 per month. Virginia-based commercial insurers and Medicaid require prior authorization for the HIV-lipodystrophy indication, typically demanding:

• Confirmed HIV diagnosis with documentation from an infectious disease or primary care provider
• Body-imaging or clinical evidence of excess visceral fat
• Stable antiretroviral regimen for at least 8 weeks
• Absence of active malignancy (tesamorelin is contraindicated in patients with active malignancy due to IGF-1 elevation)

Out-of-pocket cost for patients without insurance or with denied PA can be addressed through the manufacturer assistance program, though that does not change the legal or prescribing requirements.

Contraindications and Safety Considerations Relevant to Prescribing Decisions

A Virginia prescriber issuing tesamorelin must screen for the FDA-labeled contraindications, because prescribing outside them creates both safety and liability exposure:

• Active malignancy
• Disruption of the hypothalamic-pituitary axis (pituitary tumor, hypophysectomy, head irradiation, head trauma)
• Pregnancy (tesamorelin is FDA Pregnancy Category X; it caused fetal harm in animal studies) [1]
• Known hypersensitivity to tesamorelin or mannitol

Patients with diabetes or pre-diabetes require closer glucose monitoring, because IGF-1 elevation can impair insulin sensitivity. The prescriber should confirm baseline HbA1c <9.0% before initiating and re-check at 12 weeks.

Summary of Legal Status by Access Route in Virginia

| Access Route | Legal? | Key Condition | |---|---|---| | Branded Egrifta or Egrifta SV via licensed pharmacy | Yes | Valid Virginia-licensed prescriber | | Telehealth prescription (synchronous AV) | Yes | Prescriber holds active Virginia license | | Compounded tesamorelin (503A, documented excipient allergy) | Conditionally | Narrow; commercial product unavailable or excipient intolerance required | | Compounded tesamorelin (503B outsourcing facility) | Conditionally | Must not be a copy of commercially available product | | Purchasing without a prescription | No | Violation of 21 U.S.C. § 353 | | Research use only (no IRB, no approved indication) | No | Requires IND application to FDA |

Virginia residents who receive tesamorelin outside a prescriber-patient relationship, from an online vendor not requiring a prescription, or from an unregistered compounding pharmacy are receiving a product that does not comply with federal law regardless of what any state law says or does not say.